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Background
Systemic hypertension is a common characteristic in acute
heart failure (HF). This increasingly common phenotype is
frequently associated with renal dysfunction and requires
renal enhancing therapies. In a canine model of HF and
acute hypertension we defined the cardiorenal actions of
M-atrial natriuretic peptide (MANP), a novel particulate
guanylyl cyclase A receptor activator (pGC-A) developed
at the Mayo Clinic, and nitroglycerin (NTG), a soluble
guanylyl cyclase (sGC) activator. Compared to native
ANP, MANP has more sustained renal enhancing, blood
pressure lowering and aldosterone inhibiting action.
Based on the expression of the pGC-A receptor in the
glomerulus, renal tubule and adrenal gland, compared to
the more widespread expression of sGC in the renal vas-
culature, we hypothesized that MANP would have a more
robust effect upon the glomerular filtration rate (GFR) and
natriuretic actions and with greater aldosterone suppres-
sing effects than sGC activation with NTG. To test these
hypotheses, we used a canine model of combined HF and
hypertension. Specifically, HF was induced by chronic (10
days) rapid right ventricular pacing (180 bmp), while
hypertension was induced by continuous angiotensin II
infusion (on day 11). We than characterized the cardiore-
nal and humoral actions of intravenous MANP (n=7),
NTG (n=7), and vehicle (n=7) infusion.
Results
Mean arterial pressure (MAP) was reduced by both
MANP (139±4 to 118±3 mmHg, p<0.05) and NTG (137
±3 to 116±4 mmHg, p<0.05); similar findings were
observed for reductions in pulmonary wedge pressure
with MANP (12±2 to 6±2 mmHg, p<0.05) and NTG
(12±1 to 6±1 mmHg, p<0.05). MANP enhanced renal
function with significant increases in GFR (38±4 to 53±5
ml/min, p<0.05), renal blood flow (132±18 to 236±23 ml/
min, p<0.05), and natriuresis (11±4 to 689±37 mEq/min,
p<0.05) with inhibition of aldosterone (32±3 to 23±2 ng/
dL, p<0.05), whereas NTG had no significant effect on
these renal parameters or aldosterone activation.
Conclusion
Our results demonstrate differential cardiorenal and adre-
nal actions of pGC activation with MANP, a novel GC-A
activator, compared to sGC stimulation with NTG in
experimental acute hypertensive HF. These renal enhan-
cing actions and concomitant aldosterone suppressing
effects make MANP, now entering clinical trials, an attrac-
tive therapeutic for HF with concomitant hypertension,
especially where renal protection is a key therapeutic goal.
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